SCYNEXIS Secures $24.8M from GSK, Advances Lead Antifungal Program SCY-247, and Extends Nasdaq Compliance
Summary
SCYNEXIS received a significant $24.8 million payment from GSK, improving its liquidity and enabling continued development of its lead antifungal candidate, SCY-247, which showed positive Phase 1 results and is advancing to Phase 2.
Key Events
-
Secured $24.8 Million from GSK
SCYNEXIS received a one-time, non-refundable payment of $24.8 million from GSK in November 2025, following the termination of the Phase 3 MARIO study for ibrexafungerp. This payment significantly enhances the company's cash position.
-
Improved Financial Outlook and Liquidity
The company reported a reduced net loss of $8.6 million in 2025, a substantial improvement from $21.3 million in 2024. With $56.3 million in cash, cash equivalents, and investments, SCYNEXIS projects sufficient capital to fund operations for at least 12 months.
-
Positive Clinical Progress for SCY-247
The oral formulation of SCY-247 completed Phase 1 studies with positive safety, tolerability, and pharmacokinetic results. An intravenous formulation Phase 1 study was initiated in Q1 2026, with a Phase 2 proof-of-concept study planned for 2026 in Invasive Candidiasis.
-
Regulatory Designations for SCY-247
SCY-247 has been granted Qualified Infectious Disease Product (QIDP) status and Fast Track designations by the FDA, which could provide regulatory exclusivity and expedite the review process if approved.
Analysis
SCYNEXIS has significantly bolstered its financial position and advanced its key pipeline asset. The $24.8 million payment from GSK, following the termination of the MARIO study, provides critical liquidity and a projected 12-month operating runway. This cash infusion is substantial for a company of this size. Concurrently, positive Phase 1 results for SCY-247, along with its progression to an intravenous formulation study and a planned Phase 2 trial, underscore the potential of its lead antifungal program. The company also successfully navigated a Nasdaq delisting threat by securing an extension, with a reverse stock split as a potential future measure. The dismissal of prior legal actions further removes a significant overhang. Investors should monitor the progress of SCY-247's clinical trials and GSK's relaunch of BREXAFEMME for continued positive momentum.
At the time of this filing, SCYX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.